New drug cocktail shows promise for Hard-to-Treat breast cancer before surgery
NCT ID NCT07618923
First seen Jun 02, 2026 · Last updated Jun 23, 2026 · Updated 4 times
Summary
This phase II trial is testing a three-drug combination given before surgery for people with intermediate-to-high risk HR-positive, HER2-low breast cancer. Participants first take dalpiciclib (a pill) plus an aromatase inhibitor (another pill) for about 4 months, followed by infusions of SHR-A1811 for another 3 months. The goal is to see how well the treatment shrinks tumors before surgery, with 20 participants enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dalpiciclib, aromatase inhibitor (anastrozole, letrozole, or exemestane), and SHR-A1811
What this could lead to
If successful, this combination could offer a more effective way to shrink tumors before surgery for people with this type of breast cancer, potentially leading to better long-term outcomes.
What could go wrong
This is a small, early-phase study with only 20 participants, so results may not apply to everyone. The drugs can cause side effects, and the treatment may not work as hoped.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.